AstraZeneca cancer drug trial prompts investors to take options cover

LONDON/NEW YORK (Reuters) - Investors in drugmaker AstraZeneca have taken defensive positions in the options market ahead of eagerly awaited results of a major trial of a lung cancer treatment, which are due any day now.